NCT02500784View on ClinicalTrials.gov

Improving Beta-2 Adrenergic Signaling in Alzheimer's Disease

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2023

Primary Completion Date

April 30, 2025

Study Completion Date

July 31, 2025

Conditions
Alzheimer's DiseaseCognitive Dysfunction
Interventions
DRUG

Formoterol A

20mg/2mL, BID inhaler for 12 months: until progression or unacceptable toxicity develops.

OTHER

Formoterol B (placebo)

2mL, BID inhaler for 12 months

Trial Locations (1)

94304

VA Palo Alto Health Care System, Palo Alto

Sponsors

Collaborators (1)

Mylan Inc.
All Listed Sponsors
collaborator

Alzheimer's Association

OTHER

collaborator

Mylan Inc.

INDUSTRY

lead

Palo Alto Veterans Institute for Research

OTHER